Loading…
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-26M | $-26M | $-12M | 319.1% | - | - |
| 2024 | $0M | $-13M | $-14M | $-12M | 205.7% | - | - |
| 2023 | $0M | $-59M | $-60M | $-8M | 64.0% | - | -1471.9% |
| 2022 | $0M | $4M | $4M | $-0M | 1.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 0.95 | 8.84 | 53.56 | 26.14 |
| Operating Income | -0.95 | -8.84 | -53.56 | -26.14 |
| EBITDA | 4.41 | -58.89 | -13.14 | -25.57 |
| EBIT | 4.41 | -59.27 | -13.54 | -26.08 |
| Pretax Income | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income Common Stockholders | 4.41 | -60.48 | -13.73 | -26.28 |
| Total Expenses | 0.95 | 8.84 | 53.56 | 26.14 |
| Interest Expense | 0 | 1.21 | 0.18 | 0.20 |
| Research And Development | 5.77 | 4.40 | 31.03 | 11.11 |
| Selling General And Administration | 0.95 | 4.44 | 22.53 | 15.03 |
| Normalized EBITDA | -0.95 | -58.89 | -4.69 | -25.63 |
| Normalized Income | 0.17 | -60.48 | -5.28 | -26.34 |
| Basic EPS | 1.84 | -19.12 | -3.50 | -8.08 |
| Diluted EPS | 1.84 | -19.12 | -3.50 | -8.08 |
| Tax Effect Of Unusual Items | 1.13 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0.21 | 0 | 0 | 0 |
| Total Unusual Items | 5.36 | 0 | -8.45 | 0.06 |
| Total Unusual Items Excluding Goodwill | 5.36 | 0 | -8.45 | 0.06 |
| Net Income From Continuing Operation Net Minority Interest | 4.41 | -60.48 | -13.73 | -26.28 |
| Reconciled Depreciation | 0.23 | 0.38 | 0.40 | 0.51 |
| Net Interest Income | 0 | -1.21 | -0.18 | -0.20 |
| Net Income From Continuing And Discontinued Operation | 4.41 | -60.48 | -13.73 | -26.28 |
| Total Operating Income As Reported | -13.72 | -8.84 | -53.56 | -26.14 |
| Diluted Average Shares | 2.40 | 3.31 | 2.93 | 3.32 |
| Basic Average Shares | 2.40 | 3.31 | 2.93 | 3.32 |
| Diluted NI Availto Com Stockholders | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income Including Noncontrolling Interests | 4.41 | -60.48 | -13.73 | -26.28 |
| Net Income Continuous Operations | 4.41 | -60.48 | -13.73 | -26.28 |
| Other Income Expense | 5.36 | -50.43 | 40.02 | 0.06 |
| Other Non Operating Income Expenses | -7.38 | -50.43 | 48.47 | 0 |
| Special Income Charges | 0 | 0 | -7.50 | 0 |
| Write Off | 0 | 0.25 | 0 | 0 |
| Restructuring And Mergern Acquisition | 0 | 0 | 7.50 | 0 |
| Gain On Sale Of Security | 5.36 | 2.71 | -0.95 | 0.06 |
| Net Non Operating Interest Income Expense | 0 | -1.21 | -0.18 | -0.20 |
| Interest Expense Non Operating | 0 | 1.21 | 0.18 | 0.20 |
| General And Administrative Expense | 0.95 | 4.44 | 22.53 | 15.03 |
| Other Gand A | 0.95 | 3.34 | 7.05 | 4.15 |
| Salaries And Wages | 5.80 | 1.10 | 15.48 | 10.88 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tevogen Bio Holdings Inc.this co. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| DocGo Inc. | DCGO | $70M | - | 0.48 | -144.9% | -0.41 |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - |
| 0.92 |
| -99.8% |
| -0.71 |
| Accuray Incorporated | ARAY | $50M | - | 0.94 | -2.0% | -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Peer Median | - | - | 1.15 | -118.2% | -0.71 | |